Style | Citing Format |
---|---|
MLA | Shafifar M, et al.. "Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development." Life Sciences, vol. 308, no. , 2022, pp. -. |
APA | Shafifar M, Mozhgani SH, Razavi Pashabayg K, Mosavat A, Karbalaei M, Norouzi M, Rezaee SA (2022). Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development. Life Sciences, 308(), -. |
Chicago | Shafifar M, Mozhgani SH, Razavi Pashabayg K, Mosavat A, Karbalaei M, Norouzi M, Rezaee SA. "Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development." Life Sciences 308, no. (2022): -. |
Harvard | Shafifar M et al. (2022) 'Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development', Life Sciences, 308(), pp. -. |
Vancouver | Shafifar M, Mozhgani SH, Razavi Pashabayg K, Mosavat A, Karbalaei M, Norouzi M, et al.. Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development. Life Sciences. 2022;308():-. |
BibTex | @article{ author = {Shafifar M and Mozhgani SH and Razavi Pashabayg K and Mosavat A and Karbalaei M and Norouzi M and Rezaee SA}, title = {Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development}, journal = {Life Sciences}, volume = {308}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Shafifar M AU - Mozhgani SH AU - Razavi Pashabayg K AU - Mosavat A AU - Karbalaei M AU - Norouzi M AU - Rezaee SA TI - Selective Apc-Targeting of a Novel Fc-Fusion Multi-Immunodominant Recombinant Protein (Ttax-Tenv:Mfcγ2a) for Htlv-1 Vaccine Development JO - Life Sciences VL - 308 IS - SP - EP - PY - 2022 ER - |